Philipp du Cros

Treatment Outcomes for Serious Infections Caused by Methicillin‐Resistant<i>Staphylococcus aureus</i>with Reduced Vancomycin Susceptibility

Benjamin P. Howden, Peter Ward, Patrick G. P. Charles et al. · Clinical Infectious Diseases · 2004 · 485 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · New England Journal of Medicine · 2022 · 352 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays

Adam Penn‐Nicholson, Sivaramakrishnan N. Gomathi, César Ugarte‐Gil et al. · European Respiratory Journal · 2021 · 119 citations · Full text

Public Health, Infectious Disease Control, Infectious Diseases +16

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · The Lancet Respiratory Medicine · 2023 · 96 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +12

Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

S.K. Abidi, Jay Achar, M.M. Assao Neino et al. · European Respiratory Journal · 2019 · 88 citations · Full text

Public Health, Pharmacotherapy, Clinical Epidemiology +16